News & Updates

Women experiencing heavy or prolonged menstrual bleeding during the menopause transition appear to be predisposed to fatigue, according to a study.

Twice-daily application of ruxolitinib cream appears effective and well tolerated in the treatment of mild-to-moderate atopic dermatitis (AD) regardless of age, based on a pooled analysis of three phase III trials presented at AAAAI/WAO 2025.

Women who are socially vulnerable appear to have worse urinary incontinence and poorer incontinence-related quality of life, according to a study.

Supplementation with high-dose vitamin D in patients with clinically isolated syndrome typical for multiple sclerosis (MS) helps lower disease activity, as shown in the D-Lay MS trial.

A recent study has shown the safety and feasibility of omitting ureteral stent placement during robot-assisted radical cystectomy with intracorporeal ileal conduit (RARC-IC).

Treatment with two doses of depemokimab results in sufficient concentrations to adequately control blood eosinophil counts (BEC) over 1 year, as shown in the ANCHOR 1 and 2 trials. This finding suggests sustained anti-interleukin-5 (IL-5) biological effect and impact on type 2 inflammation.

Using tranexamic acid (TXA) appears to lessen blood loss and the need for perioperative blood transfusion (PBT) without increasing the risk of venous thromboembolism (VTE) in patients with bladder cancer undergoing radical cystectomy, reports a study.

Omalizumab remains superior to oral immunotherapy (OIT) for the treatment of multi-food allergies with fewer adverse effects in Stage 2 of the NIH*-sponsored phase III OUtMATCH** study, the first head-to-head trial comparing the two treatments.

For individuals who completed treatment for pulmonary tuberculosis (TB), vaccination with H56:IC31 does not appear to reduce the risk of disease recurrence, according to a phase 2b trial.

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.